Clinical trial · Interventional
Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS
Phase I/II Evaluation of Safety and Activity of Mylotarg Plus Melphalan and Fludarabine as Preparative Therapy for Older or Medically Infirm Patients Undergoing Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical research study is to find the highest safe dose of Mylotarg that can be combined with chemotherapy in patients receiving allogeneic bone marrow transplantation. Researchers will study the effects of this treatment combination on patients with high-risk acute leukemia, chronic myelogenous leukemia, or myelodysplastic syndrome. Primary Objective: 1\. To determine the safety and maximum tolerated dose of Mylotarg as part of a reduced-intensity preparative regimen patients undergoing related, mismatched-related or matched unrelated donor transplantation. Secondary Objectives: 1. To evaluate response rates, engraftment kinetics and degree of chimerism achievable with this strategy. 2. To evaluate the incidence and severity of GVHD in this population 3. To evaluate disease-free and overall survival and relapse rates.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myelogenous Leukemia | Acute Myeloid Leukemia | ALIAS | 0.90 |
| Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | ONTOLOGY_EXACT | 0.98 |
| Myelodysplastic Syndrome | Myelodysplastic Syndrome | CURATED_BROADER | 0.80 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Anti-thymocyte globulin | Drug | — | UNRESOLVED |
| Fludarabine | Drug | Fludarabine | ALIAS |
| Melphalan | Drug | Melphalan | ALIAS |
| Mylotarg | Drug | Gemtuzumab Ozogamicin | ALIAS |
| Stem cell transplant | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Chemotherapy + ATG + Stem Cell Infusion
- interventionNames
- Drug: Mylotarg
- Drug: Fludarabine
- Drug: Melphalan
- Drug: Anti-thymocyte globulin
- Procedure: Stem cell transplant
Primary outcomes (1)
- measure
- Maximum Tolerated Dose (MTD) of Mylotarg as Determined by Number of Participants With Dose Limiting Toxicity (DLT) at Each Dose Level
- timeFrame
- Followed in outpatient clinic from day -12 (prior to transplant) thru day -6 with each dose level
Secondary outcomes (1)
- measure
- Patient Response
- timeFrame
- Continously over first 30 days
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 12 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Patients 12-75 years of age * Patients are eligible if deemed ineligible for conventional high dose chemotherapy programs because of concurrent medical conditions. Patients with refractory AML are always eligible if ejection fraction \> 35, FEV1, FVC, or DLCO \> 40%, abnormal LFT's. * Patients must have recovered from previous Grade III-IV toxicity due to prior anti-neoplastic therapy (except alopecia). * Patients with the following disease categories will be eligible: 1. AML with induction failure, relapse or 2nd remission 2. MDS with IPI INT-2 or High-risk disease (Appendix 4) or CMML 3. CML in accelerated phase or blast crisis 4. Interferon or STI resistant CML not eligible for conventional stem cell transplant * Patients receiving prior BMT are eligible. If myeloablative chemoradiotherapy was used in the prior transplant patients must be \>90 days from transplant. If non-myeloablative therapy was used patients must be \>30 days post-transplant. * Leukemia cells must express cell surface CD33 evaluated by flow cytometry in \> 20% of leukemia cells. * Patients must have an HLA-compatible related donor (6/6 or 5/6 HLA-match) capable of donating bone marrow or G-CSF stimulated peripheral blood stem cells using aphereses techniques or a 6/6 HLA matched unrelated bone marrow donor (serologic matching for Class I, molecular matching for DR?1). * Patients must have a ECOG PS\<2 (Appendix 6), Cr\<2.0, bilirubin \<2, and (SGPT) \<3x normal * Patients must have an estimated life expectancy \> 3 months * Patient and donor must sign informed consent. Unrelated donors will be consented according to the National Donor Marrow Registry policy Exclusion Criteria: * uncontrolled active infection * HIV disease * pregnancy and nursing * active, uncontrolled CNS leukemia
References
Publications (0)
Data not yet available